Across the globe, the available classes of antiretroviral drugs have substantially reduced the HIV-related mortality. According to the latest report “Global HIV Therapeutics Market Analysis” by RNCOS, some of the key drugs in the late stage of the pipeline, including Cobicistat and Elvitegravir by Gilead Sciences, and GSK-1349572 by ViiV Healthcare and Shionogi, among others, are likely to influence the global HIV therapeutics market in the coming years. Once commercialized, these drugs would positively impact the therapeutic process associated with the HIV/AIDS, and lead to an intense competition in the market.
As per UNAIDS data, there were a total of 33.3 Million HIV victims in the world till 2009-end. A significant opportunity exists for pharmaceutical firms in the US$ 12.6 Billion global HIV therapeutics market which is backed by factors like technological innovations and huge potential for combination products. The report by RNCOS not only focuses on the key regions of the world to illustrate the state of HIV/AIDS therapeutics market and developments in these countries, but also provides an in-depth insight into the market’s key aspects, and comprehensive overview about the drugs under development.
Summarizing the details on major brands in the HIV/AIDS therapeutics sector, the study provides a careful analysis of the fast growing market for the HIV therapeutics. It also discusses about the key industry developments, such as licensing agreements and drug approvals. By and large, it provides optimum knowledge to clients who want to get an insight into the global HIV/AIDS therapeutics market.
Some of our Related Reports are:
|
